Cargando…

Strategies of LncRNA DLX6-AS1 on Study and Therapeutics

Accumulating evidence has revealed the vital regulatory roles of lncRNA DLX6-AS1 in various tumors at pre-transcriptional, transcriptional, and post-transcriptional levels, which makes it a potential prognosis factor and therapeutic target. In addition, the presence of lncRNA DLX6-AS1 in the exosome...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yanyan, Li, Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198352/
https://www.ncbi.nlm.nih.gov/pubmed/35719380
http://dx.doi.org/10.3389/fgene.2022.871988
_version_ 1784727595168825344
author Zhao, Yanyan
Li, Pei
author_facet Zhao, Yanyan
Li, Pei
author_sort Zhao, Yanyan
collection PubMed
description Accumulating evidence has revealed the vital regulatory roles of lncRNA DLX6-AS1 in various tumors at pre-transcriptional, transcriptional, and post-transcriptional levels, which makes it a potential prognosis factor and therapeutic target. In addition, the presence of lncRNA DLX6-AS1 in the exosomes of peripheral blood of patients with tumors may also contribute to it being a possible cancer-related biomarker. However, most literature studies are devoted to studying the effect of lncRNA DLX6-AS1 as a sponging molecule of miRNAs, the research of which is likely to get stuck into a dilemma. Literature studies published already have demonstrated an exciting cell malignant phenotype inhibition with the knockdown of lncRNA DLX6-AS1 in various tumor cell lines. With the comprehensive development of delivery systems, high-throughput sequencing, and aptamers, the problems of finding novel research methods and exploring the therapeutic options which are based on lncRNA DLX6-AS1 in vivo could come into a period to deal with. This review aims to summarize the research statuses of lncRNA DLX6-AS1, discuss other study methodologies and therapeutic strategies on it, which might be of help to the deep learning of lncRNA DLX6-AS1 and its application from basic to clinical research.
format Online
Article
Text
id pubmed-9198352
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91983522022-06-16 Strategies of LncRNA DLX6-AS1 on Study and Therapeutics Zhao, Yanyan Li, Pei Front Genet Genetics Accumulating evidence has revealed the vital regulatory roles of lncRNA DLX6-AS1 in various tumors at pre-transcriptional, transcriptional, and post-transcriptional levels, which makes it a potential prognosis factor and therapeutic target. In addition, the presence of lncRNA DLX6-AS1 in the exosomes of peripheral blood of patients with tumors may also contribute to it being a possible cancer-related biomarker. However, most literature studies are devoted to studying the effect of lncRNA DLX6-AS1 as a sponging molecule of miRNAs, the research of which is likely to get stuck into a dilemma. Literature studies published already have demonstrated an exciting cell malignant phenotype inhibition with the knockdown of lncRNA DLX6-AS1 in various tumor cell lines. With the comprehensive development of delivery systems, high-throughput sequencing, and aptamers, the problems of finding novel research methods and exploring the therapeutic options which are based on lncRNA DLX6-AS1 in vivo could come into a period to deal with. This review aims to summarize the research statuses of lncRNA DLX6-AS1, discuss other study methodologies and therapeutic strategies on it, which might be of help to the deep learning of lncRNA DLX6-AS1 and its application from basic to clinical research. Frontiers Media S.A. 2022-06-01 /pmc/articles/PMC9198352/ /pubmed/35719380 http://dx.doi.org/10.3389/fgene.2022.871988 Text en Copyright © 2022 Zhao and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Zhao, Yanyan
Li, Pei
Strategies of LncRNA DLX6-AS1 on Study and Therapeutics
title Strategies of LncRNA DLX6-AS1 on Study and Therapeutics
title_full Strategies of LncRNA DLX6-AS1 on Study and Therapeutics
title_fullStr Strategies of LncRNA DLX6-AS1 on Study and Therapeutics
title_full_unstemmed Strategies of LncRNA DLX6-AS1 on Study and Therapeutics
title_short Strategies of LncRNA DLX6-AS1 on Study and Therapeutics
title_sort strategies of lncrna dlx6-as1 on study and therapeutics
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198352/
https://www.ncbi.nlm.nih.gov/pubmed/35719380
http://dx.doi.org/10.3389/fgene.2022.871988
work_keys_str_mv AT zhaoyanyan strategiesoflncrnadlx6as1onstudyandtherapeutics
AT lipei strategiesoflncrnadlx6as1onstudyandtherapeutics